View in EDS

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Saved in:
Bibliographic Details
Title: Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Authors: Owen RG; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., McCarthy H; Royal Bournemouth Hospital, Bournemouth, United Kingdom., D'Sa S; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Thomas SK; MD Anderson Cancer Center, Houston, TX., Tournilhac O; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, EA7453 CHELTER and CIC-1405, Université Clermont Auvergne, Clermont-Ferrand, France., Forconi F; Cancer Care and Cancer Sciences, Faculty of Medicine, University of Southampton Hospital Trust, Southampton, United Kingdom., Kersten MJ; Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Iyengar S; Royal Marsden Hospital, London, United Kingdom., Kothari J; Churchill Hospital, Oxford, United Kingdom., Minnema MC; Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Cheson BD; Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC., Walter HS; Ernest and Helen Scott Haematological Research Institute and Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom., Greenwald D; University of California, Los Angeles, Santa Barbara Cancer Center, Santa Barbara, CA., Calvo R; AstraZeneca, Gaithersburg, MD., Li Y; AstraZeneca, South San Francisco, CA., Rule S; AstraZeneca, Mississauga, ON, Canada., Furman RR; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.
Source: Blood advances [Blood Adv] 2026 Jul 28; Vol. 10 (14), pp. 5058-5069.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41985004
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Owen+RG%22">Owen RG</searchLink>; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McCarthy+H%22">McCarthy H</searchLink>; Royal Bournemouth Hospital, Bournemouth, United Kingdom.<br /><searchLink fieldCode="AU" term="%22D'Sa+S%22">D'Sa S</searchLink>; University College London Hospitals NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Thomas+SK%22">Thomas SK</searchLink>; MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Tournilhac+O%22">Tournilhac O</searchLink>; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, EA7453 CHELTER and CIC-1405, Université Clermont Auvergne, Clermont-Ferrand, France.<br /><searchLink fieldCode="AU" term="%22Forconi+F%22">Forconi F</searchLink>; Cancer Care and Cancer Sciences, Faculty of Medicine, University of Southampton Hospital Trust, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kersten+MJ%22">Kersten MJ</searchLink>; Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Zinzani+PL%22">Zinzani PL</searchLink>; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Iyengar+S%22">Iyengar S</searchLink>; Royal Marsden Hospital, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kothari+J%22">Kothari J</searchLink>; Churchill Hospital, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Minnema+MC%22">Minnema MC</searchLink>; Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kastritis+E%22">Kastritis E</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Cheson+BD%22">Cheson BD</searchLink>; Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.<br /><searchLink fieldCode="AU" term="%22Walter+HS%22">Walter HS</searchLink>; Ernest and Helen Scott Haematological Research Institute and Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Greenwald+D%22">Greenwald D</searchLink>; University of California, Los Angeles, Santa Barbara Cancer Center, Santa Barbara, CA.<br /><searchLink fieldCode="AU" term="%22Calvo+R%22">Calvo R</searchLink>; AstraZeneca, Gaithersburg, MD.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; AstraZeneca, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Rule+S%22">Rule S</searchLink>; AstraZeneca, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Furman+RR%22">Furman RR</searchLink>; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 Jul 28; Vol. 10 (14), pp. 5058-5069.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41985004
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025017713
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5058
    Titles:
      – TitleFull: Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Owen RG
      – PersonEntity:
          Name:
            NameFull: McCarthy H
      – PersonEntity:
          Name:
            NameFull: D'Sa S
      – PersonEntity:
          Name:
            NameFull: Thomas SK
      – PersonEntity:
          Name:
            NameFull: Tournilhac O
      – PersonEntity:
          Name:
            NameFull: Forconi F
      – PersonEntity:
          Name:
            NameFull: Kersten MJ
      – PersonEntity:
          Name:
            NameFull: Zinzani PL
      – PersonEntity:
          Name:
            NameFull: Iyengar S
      – PersonEntity:
          Name:
            NameFull: Kothari J
      – PersonEntity:
          Name:
            NameFull: Minnema MC
      – PersonEntity:
          Name:
            NameFull: Kastritis E
      – PersonEntity:
          Name:
            NameFull: Cheson BD
      – PersonEntity:
          Name:
            NameFull: Walter HS
      – PersonEntity:
          Name:
            NameFull: Greenwald D
      – PersonEntity:
          Name:
            NameFull: Calvo R
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Rule S
      – PersonEntity:
          Name:
            NameFull: Furman RR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 07
              Text: 2026 Jul 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1